Loading clinical trials...
Loading clinical trials...
Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer
Conditions
Interventions
Cytoreductive Surgery (CRS)
Adjuvant Chemotherapy
+6 more
Locations
1
United States
Mercy Medical Center
Baltimore, Maryland, United States
Start Date
April 1, 2014
Primary Completion Date
August 1, 2027
Completion Date
April 1, 2028
Last Updated
November 19, 2024
NCT06915025
NCT04550494
NCT05039801
NCT07432633
NCT07144826
NCT05334069
Lead Sponsor
Mercy Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions